CSL to buy back $723M of its shares

Australia's CSL, which completed its acquisition of Novartis' ($NVS) flu vaccines business this year, has launched a AU$1 million share buyback. It is the ninth buyback for the company in the past 10 years and also the biggest it has ever undertaken. "Our ability to undertake another buyback of this scale is testament to CSL's strong financial position and excellent cashflow," CSL chairman John Shine told shareholders at the company's annual general meeting on Thursday. More

Suggested Articles

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

GSK's Shingrix has nabbed a huge chunk of the U.S. shingles-shot market, just five months after it was approved by the FDA.